Cinacalcet hydrochloride is classified as a calcimimetic medication approved by the US Food and Drug Administration (FDA) for the management of secondary hyperparathyroidism associated with end-stage kidney disease and primary hyperparathyroidism in cases where surgical intervention is not feasible. Cinacalcet is also used off-label for the treatment of calciphylaxis in patients with advanced kidney disease or undergoing dialysis.Cinacalcet’s primary indication is to lower the parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism associated with end-stage kidney disease. Cinacalcet is crucial in treating chronic kidney disease (CKD) by decreasing serum PTH levels and preventing bone deterioration in patients who frequently experience elevated phosphorus and PTH levels and fluctuating calcium levels. Cinacalcet can be utilized for treating primary hyperparathyroidism in individuals who are not suitable candidates for surgery or for whom surgery poses a high risk. By lowering PTH and serum calcium levels, cinacalcet can be combined with bisphosphonates to diminish calcium resorption from bone. Cinacalcet is often used off-label as a treatment regimen for individuals with calciphylaxis—a condition that can occur in patients with end-stage kidney disease.This activity reviews the indications, mechanism of action, adverse event profile, and other relevant interactions of cinacalcet pertinent to interprofessional healthcare team members involved in treating patients with hyperparathyroidism and related conditions. This activity allows healthcare professionals to customize treatment strategies tailored to each patient’s needs by making well-informed decisions, optimizing dosage regimens, and minimizing the risk of adverse reactions, thereby delivering precise and personalized care and improving patient outcomes.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/40477
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABOHNS - 1.0 Point; Credit Type(s): Self-Assessment (ABOHNS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Chemical Pathology, Complex General Surgical Oncology, Endocrine, Endocrinology, Diabetes, and Metabolism, General Pediatrics, General Surgery, Head & Neck, Hospital Medicine, Internal Medicine, Medical Oncology, Nephrology, Pediatric Endocrinology, Pediatric Nephrology